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 Implication for health policy/practice/research/medical edu-
cation:
This article focuses on HCV infection among intravenous drug 
users. Considering high prevalence of HCV among intravenous 
drug users and its effect in public health. This study is recom-
mended to epidemiologists, hematologist, and infectious dis-
eases specialists.
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HCV infection is a global public health problem and 
can progress to cirrhosis, hepatic decompensation, he-
patocellular carcinoma, and death, with asymptomatic 
conditions and few short-term effects in the beginning 
(1, 2). It is expected that over the next decade, despite a 
declining  incidence  of  new  infections,  mortality  and 
associated costs will increase (1). Worldwide prevalence 
rates range from 0.01 to 20%, and the World Health Or-
ganization (WHO) estimates that up to 3% of the world’s 
population (170 million) have been infected with HCV (3). 
Worldwide hepatitis C data show significant prevalence 
rates in high-risk populations, ranging from 30% to 50%, 
with injecting drug use being the predominant risk fac-
tor (4, 5). In most cases, HCV is spread parenterally, and 
research has identified intravenous and intranasal drug 
use, exposure to infected blood and blood products, and 
high-risk behaviors as risk factors in parenteral transmis-
sion (1). The variation in HCV prevalence creates the need 
for different preventive methods, community interven-
tions, and therapeutic strategies based on economic and 
social variance (6). Drug addicts are a high-risk group for 
acquiring one or more parenterally transmitted infec-
tion, such as HIV, HCV, HBV and HTLV-1 (7).
In Iran opiates are the most commonly abused drug 
type, and it has been estimated that 2.8% of adults ages 
15 to 64 are opiate abusers (8, 9). Also, data from the 2006 
Spengler Forum Index revealed that 12.2% (180,000) of 
drug abusers were injecting drug users (IDUs; [10]). An-
other study that year with a different dataset estimated 
that there were 200 to 300 thousand IDUs with a mean 
age of 33 ± 8.9 years in Iran (11). Nearly 40% of Iranian 
prisoners were IDUs, and the prevalence of HCV infection 
among this population has been reported to be between 
38 and 90% (12, 13). HCV seroprevalence among prison in-
mates varies markedly from country to country, but as a 
whole, research has shown that drug-abusing prisoners 
and habitual injectors were 90 times more likely than 
healthy blood donors and the general population to be 
infected with HCV (14-16). The risk of testing positive for 
HCV among prisoners was found to be associated with 
marital status, duration of drug use, IV drug use, shared 
injection equipment, duration of incarceration, tattoos, 
and number of times in prison (13). The point prevalence 
of sterile-syringe use was 85% among IDUs, but a history 
of sharing injection equipment was reported between 
50 and 70% of them (9, 17). Another study has shown that 
tattoos might have a higher risk of HCV infection when 
given in prison (18). Mirahmadizadeh et al. found that 
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the proportions of unsafe and unprotected homo- and 
heterosexual contact among IDUs were 19.4% and 37.4 %, 
respectively (19).
Today, injecting drug abuse is a major and perhaps the 
most important risk factor for HCV infection (20). Intra-
venous drug abusers not only have the highest preva-
lence  of  HCV  infection  but  also  constitute  a  potential 
reservoir of HCV in the community (6). Injecting drug 
use and health care provision are the most important 
risk factors for HCV infection, and the number of HCV-
infected persons continues to grow (21). In early reports 
from Tehran in 2001 by Zali et al., ELISA tests were HCV 
Ab positive for 45% of imprisoned IDUs (22). About 38% of 
IDU prisoners in the western province of Hamadan, 47% 
in the northwestern province of Zanjan, 52% in Tehran, 
64.8% in the southern cities of Bandar Abbas and Roodan, 
and 88.9% in the northern of Guilan were HCV Ab posi-
tive, whereas the rate in non-IDUs in prison was much 
lower (1, 13, 23, 24). Iran has one of the highest per capita 
numbers of opioid users in the world, with a substantial 
and potentially growing proportion of IDUs (8, 9). The 
dramatic growth in the number of prisoners involved in 
high-risk behaviors and the high rates of community re-
entry emphasize the need for screening, detection, and 
treatment of HCV infection as well as harm-reduction 
programs to help curtail the rise of HCV infection in in-
carcerated populations and the general population (1). 
Because many drug users spend time in prison, it is an 
appropriate to break the cycle of infection by multidis-
ciplinary interventional approaches targeted at control-
ling the further spread of these infections among prison-
ers and to the general population. Intervention efforts 
have expanded progressively to include comprehensive 
HIV prevention with epidemiological surveillance, edu-
cational programs, research activities, and methadone-
maintenance therapy, but they must further incorporate 
components such as HCV-specific educational programs 
and encourage inmates to avoid tattooing while in pris-
on (25).
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